This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB04879/identifier/drugbank/

Statements

Subject Item
n2:DB04879
rdf:type
n3:Drug
n3:description
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
n3:generalReferences
# Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17584317 # Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17616257 # Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16882767
n3:group
investigational
n3:halfLife
Approximately 6 hours.
n3:indication
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
owl:sameAs
n13:DB04879
dcterms:title
Vatalanib
adms:identifier
n6:4851 n7:PA7001 n8:151194 n9:133257 n10:DB04879 n11:10318716
n3:mechanismOfAction
Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
n3:synonym
PTK 787 PTK/ZK 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate
n3:IUPAC-Name
n4:271B5C5A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C60-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C5F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C5C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C5D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C5E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C58-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C59-363D-11E5-9242-09173F13E4C5 n4:271B5C56-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C57-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5C66-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C67-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C61-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C62-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C64-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C63-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C65-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid onset of absorption
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
212141-54-3
n3:category
n3:Bioavailability
n4:271B5C6C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C6E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C6F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C6B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C6A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C6D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C5B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C68-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C69-363D-11E5-9242-09173F13E4C5